Brian Dow is a seasoned finance executive experienced in financing and transitioning private pre-commercial companies to public commercial enterprises. Mr. Dow is currently Chief Financial Officer for ProSomnus® Sleep Technologies (NASDAQ: OSA), a high growth commercial stage medical device company. Prior to joining ProSomnus during 2023, Mr. Dow served as Chief Financial Officer of Agendia N.V., a $60 million molecular diagnostics company, Senior Vice President and Chief Financial Officer of Pulse Biosciences (NASDAQ: PLSE), a development stage medical device company, and Principal Accounting Officer for Pacific Biosciences (NASDAQ: PACB), a commercial stage developer, manufacturer and provider of next generation sequencing instruments. Mr. Dow started his career as a manager with Ernst & Young.
Mr. Dow holds a B.S. in Management from the Georgia Institute of Technology and is recognized as a licensed certified public accountant by the Washington State Board of Accountancy.